Skip to main content

MS news

Our news web pages include ground-breaking multiple sclerosis news and research from around the world. 

These news stories are taken from external sources and as such, MS-UK does not verify, endorse or accept responsibility for their content.

Some of these pages have been written for medical professionals and this can be reflected in the complexity of language and content.

Supporting you

We’re here to support you, whether you are awaiting a diagnosis of multiple sclerosis or have been living with the condition for years. 

Find out more about the MS-UK Helpline

Find out more about our Choices booklets

Find out more about New Pathways magazine

 


Eleven-year-old Asher Walton-Mitchell from Sheffield has raised more than £1, 300 after writing to 400 neighbours and asking them for help. Asher's neighbour Phil Waterworth, a former teacher who has...
Simvastatin, a widely prescribed cholesterol lowering drug, may slow brain atrophy and disease progression in secondary progressive multiple sclerosis (SPMS) for reasons unrelated to changes in blood...
Alterations in the composition of microbes in the gut may influence childhood MS. That’s according to research carried out by Dr. Helen Tremlett, PhD, of the University of British Columbia in Canada...
Treatment with Ocrevus (ocrelizumab) decreased levels of neurofilament light chain (NfL) and immune B-cells in the blood serum and central nervous system of patients with relapsing MS, according to...
Rates of sexual dysfunction and related distress are higher among women with MS than those without the condition. That is according to research published in the Journal of Sexual Medicine. In the...
A new 48-week study of the investigational drug evobrutinib in patients with relapsing remitting MS (RRMS) showed it reduced the number of enhanced MRI lesions (T1 gadolinium-enhancing lesions) among...
The National Institute for Health and Care Excellence (NICE) has approved ocrelizumab (Ocrevus) for treating patients in England with early primary progressive multiple sclerosis (PPMS). Patients...
The European Medicines Agency (EMA) has started a review of the multiple sclerosis medicine Lemtrada (alemtuzumab) following new reports of a range of potentially serious side effects. These side...
Healthcare Improvement Scotland has published revised standards to help health and social care professionals improve the care and support provided for the estimated one million adults in Scotland...
Inflammation and demyelination are the main processes in multiple sclerosis (MS). However, to date, blood biomarkers of inflammation are lacking. TWEAK, a transmembrane protein that belongs to the...

Pages